Investors

Esperance Pharmaceuticals is proud of the caliber of its three founding investors: Louisiana Fund I, Themelios Venture Partners, and Research Corporation Technologies.  The founding investors serve as the Board of Directors of the Company with each represented by a key member of the investor company.

Louisiana Fund I (LFI) (www.louisianafund.com) is an early-stage venture capital fund focused on the identification of investment opportunities emanating from research Universities and other organizations in the state of Louisiana.  Louisiana Fund I targets companies developing commercially promising technologies with an emphasis on those originating in Louisiana universities. Areas of interest include pharmaceuticals, biotechnology, agritechnology, information technology and other high
technology opportunities that offer venture capital returns.  Louisiana Fund I is represented by Joseph F. Lovett, Managing General Partner.

Themelios Ventures, LP is one of the investment funds managed by BVM Capital LLC (www.bvmcap.com), a southeast U.S. based venture capital firm that provides equity capital to early and expansion stage companies with proprietary technology platforms or unique products addressing large markets. Themelios invests in both life sciences technologies originating from the Pennington Biomedical Research Center in Baton Rouge, Louisiana, and in companies outside of the Pennington Center that run clinical trials or conduct research collaborations with the Center. Themelios is represented by Ross P. Barrett, Managing General Partner.

Louisiana Technology Fund (LTF) was established to invest solely in Louisiana’s emerging technology companies. LTF is an effort from the states four research parks and Louisiana’s Certified Capital Companies (CAPCOs) and is designed exclusively for investing in early-stage, Louisiana technology companies. The fund was initially capitalized by Advantage Capital Partners, Enhanced Capital and Whitecap Louisiana Growth Fund. LTF is represented by Justin N. Obletz, Vice President, Advantage Capital Partners.

BVM Capital LLC is a southeast U.S. based venture capital firm that provides equity capital to early and expansion stage companies with proprietary technology platforms or unique products addressing large markets. BVM Capital manages several investment funds including Louisiana Ventures, the Themelios Funds and TransBio Ventures, LP.

Sanofi Genzyme Bioventures: Sanofi Genzyme (SGBV) is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. Genzyme became part of Sanofi in 2011. Founded as Genzyme in Boston in 1981, Sanofi Genzyme rapidly grew to become one of the world’s leading biotechnology companies, recognized for pioneering development of treatments for rare genetic disorders and innovative contributions to medical science and biomanufacturing.